Destiny Pharma
Ticker: DEST Exchange: AIM

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Webinar recording on Phase 2b study results

Watch CEO Neil Clark and CFO Shaun Claydon discuss the 'outstanding' outcome of the trial for XF-73, their nasal gel in development to prevent post-surgical infection. 

They also address multiple diverse questions from the investors' audience, and the video lasts 37 minutes in total.

See it here: 

26810392321 - destiny-pharma
Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates